Pfizer and Takeda, which previously backed a $15m series A, have returned to back a $76m series B round for Cortexyme.

US-based degenerative diseases treatment developer Cortexyme has raised $76m in a series B round from investors including Verily Life Sciences, the life sciences subsidiary of diversified conglomerate Alphabet. Pharmaceutical firms Pfizer and Takeda, through its Takeda Ventures unit, also participated in the round, as did Sequoia Capital, Vulcan Capital, Epiq Capital Group, RSL Investments, Huizenga…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.